Literature DB >> 11916236

Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.

A V Lee1, X Cui, S Oesterreich.   

Abstract

Since the cloning of the estrogen receptor alpha (ERalpha) and subsequent identification of a second distinct form of ER, termed ERbeta, a large volume of research has begun to define the molecular mechanisms of ER action. However, although great progress has been made, ER action is still poorly understood. It is expected that a better understanding of ER action may lead to novel strategies and targets for breast cancer prevention and treatment. One of the early-realized functions of the ER was regulation of growth factor signaling, but the degree of interaction between these two mitogenic signaling pathways could not have been anticipated. Recent evidence suggests that the ER and the growth-factor-signaling pathways intersect and directly interact at every level of signal transduction. The resulting synergism between ER and growth factors has been documented both in normal breast development and, importantly, in breast cancer progression and antiestrogen resistance. In this review, we will highlight our current understanding of the molecular mechanisms of cross-talk between ER and growth-factor-signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11916236

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

Review 1.  The changing role of ER in endocrine resistance.

Authors:  Agostina Nardone; Carmine De Angelis; Meghana V Trivedi; C Kent Osborne; Rachel Schiff
Journal:  Breast       Date:  2015-08-10       Impact factor: 4.380

2.  Estrogen receptor expression in sporadic vestibular schwannomas.

Authors:  Carrie M Brown; Zana K Ahmad; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-01       Impact factor: 2.311

3.  Innate Immunity in the Female Reproductive Tract: Role of Sex Hormones in Regulating Uterine Epithelial Cell Protection Against Pathogens.

Authors:  Daniel O Ochiel; John V Fahey; Mimi Ghosh; Severina N Haddad; Charles R Wira
Journal:  Curr Womens Health Rev       Date:  2008-05

Review 4.  The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.

Authors:  Jordyn Kreutzfeldt; Brett Rozeboom; Nandini Dey; Pradip De
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

Review 5.  From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?

Authors:  Victoria Shang Wu; Noriko Kanaya; Chiao Lo; Joanne Mortimer; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-18       Impact factor: 4.292

6.  Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro.

Authors:  Pushpendra Singh; Felix Bast
Journal:  Med Oncol       Date:  2015-08-23       Impact factor: 3.064

Review 7.  Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications.

Authors:  Mario Giuliano; Meghana V Trivedi; Rachel Schiff
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

8.  Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability.

Authors:  Matthew J Sikora; Michael D Johnson; Adrian V Lee; Steffi Oesterreich
Journal:  Endocrinology       Date:  2016-07-26       Impact factor: 4.736

9.  HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

Authors:  Paul Haluska; Joan M Carboni; Cynthia TenEyck; Ricardo M Attar; Xiaonan Hou; Chunrong Yu; Malvika Sagar; Tai W Wong; Marco M Gottardis; Charles Erlichman
Journal:  Mol Cancer Ther       Date:  2008-09-02       Impact factor: 6.261

10.  Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.

Authors:  Jiajun Cui; Katherine Germer; Tianying Wu; Jiang Wang; Jia Luo; Shao-chun Wang; Qianben Wang; Xiaoting Zhang
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.